Advertisement

International Journal of Legal Medicine

, Volume 133, Issue 3, pp 811–820 | Cite as

Phenotypic effects of chronic and acute use of methiopropamine in a mouse model

  • Federica Foti
  • Matteo Marti
  • Andrea Ossato
  • Sabrine Bilel
  • Eugenio Sangiorgi
  • Francesco Botrè
  • Bruna Cerbelli
  • Alfonso Baldi
  • Fabio De-GiorgioEmail author
Original Article

Abstract

Methiopropamine (MPA) is a structural analogue of methamphetamine and belongs to the category of the novel psychoactive substances. To the best of our knowledge, no experimental study has been performed to evaluate the organ damage evoked by MPA administration in an animal model. Therefore, the main purpose of the present study was to investigate the histological changes in CD-1 male mice following the chronic administration of MPA. MPA-chronically treated mice showed myocardial damage with features consistent with repeated episodes of ischemia and a pattern of kidney damage and gastrointestinal ischemia, with ischemic-necrotic lesions of variable extent. In agreement with the analogies between MPA and methamphetamine, we link organ damage secondary to MPA administration to the vasoconstrictive effect exhibited by both compounds. Chronically MPA-treated mice did not show changes in body weight, food intake, thermoregulation, muscular strength and motor coordination in the accelerod test. However, acute MPA administration significantly increased their heart rate and promoted vasoconstriction, which were associated with the sudden death of a subset of animals (40% of all chronically treated mice). In conclusion, the present study demonstrates that MPA consumption could induce health hazards, highlighting the risk of sudden catastrophic events; therefore, clinicians should be aware of these data and consider MPA screening when no other drug is identified by a urine drug screen.

Keywords

Methiopropamine Novel psychoactive substances Myocardium Kidney Gastrointestinal tract Mice 

Abbreviations

NPSs

Novel psychoactive substances

MPA

Methiopropamine

METH

Methamphetamine

MI

Myocardial infarction

Notes

Acknowledgments

This study was funded by Ministero dell’Istruzione, dell’Università e della Ricerca [FIRB Project code: RBFR12LD0W, titled “L’abuso/dipendenza da anabolizzanti e nuove sostanze psicoattive (Smart Drugs) quale piaga sociale di interesse sanitario e giuridico. Danni d’organo nella popolazione sportiva giovanile: evidenze epidemiologiche, biochimiche, patologiche, tossicologiche e meccanismi di controllo”]. This research was also funded by the Drug Policies Department, Presidency of the Council of Ministers, Italy [project NS-Drugs to M Marti] and by local funds from the University of Ferrara [grant number FAR 2016 and FAR 2017 to M. Marti].

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to declare.

References

  1. 1.
    Council Decision 2005/387/JHA (2005) of 10 May 2005 on the information exchange, risk assessment and control of new psychoactive substances. Off J L 127: 32–37. Available at http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32005D038. Accessed 26 July 2018
  2. 2.
    Zawilska JB (2015) "Legal highs"—an emerging epidemic of novel psychoactive substances. Int Rev Neurobiol 120:273–300.  https://doi.org/10.1016/bs.irn.2015.02.009 CrossRefGoogle Scholar
  3. 3.
    Iversen L, Gibbons S, Treble R, Setola V, Huang XP, Roth BL (2013) Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol 700(1–3):147–151.  https://doi.org/10.1016/j.ejphar.2012.12.006 CrossRefGoogle Scholar
  4. 4.
    Kamijo Y, Takai M, Fujita Y, Sakamoto T (2016) A multicenter retrospective survey of poisoning after consumption of products containing novel psychoactive substances from 2013 to 2014 in Japan. Am J Drug Alcohol Abuse 42(5):513–519.  https://doi.org/10.1080/00952990.2016.1176177 CrossRefGoogle Scholar
  5. 5.
    Lee HM, Wood DM, Hudson S, Archer JR, Dargan PI (2014) Acute toxicity associated with analytically confirmed recreational use of methiopropamine (1-(thiophen-2-yl)-2-methylaminopropane). J Med Toxicol 10(3):299–302.  https://doi.org/10.1007/s13181-014-0399-y CrossRefGoogle Scholar
  6. 6.
    Daveluy A, Castaing N, Cherifi H, Richeval C, Humbert L, Faure I, Labadie M, Allorge D, Haramburu F, Molimard M, Titier K (2016) Acute methiopropamine intoxication after "synthacaine" consumption. J Anal Toxicol 40(9):758–760.  https://doi.org/10.1093/jat/bkw073 Google Scholar
  7. 7.
    Hill SL, Najafi J, Dunn M, Acheampong P, Kamour A, Grundlingh J, Blain PG, Thomas SH (2016) Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. Clin Toxicol (Philadelphia, Pa) 54(8):638–643.  https://doi.org/10.1080/15563650.2016.1190980 CrossRefGoogle Scholar
  8. 8.
    Anne S, Tse R, Cala AD (2015) A fatal case of isolated methiopropamine (1-(thiophen-2-yl)-2-methylaminopropane) toxicity: a case report. Am J Forensic Med Pathol 36(3):205–206.  https://doi.org/10.1097/paf.0000000000000170 CrossRefGoogle Scholar
  9. 9.
    Yoon HS, Cai WT, Lee YH, Park KT, Lee YS, Kim JH (2016) The expression of methiopropamine-induced locomotor sensitization requires dopamine D2, but not D1, receptor activation in the rat. Behav Brain Res 311:403–407.  https://doi.org/10.1016/j.bbr.2016.05.060 CrossRefGoogle Scholar
  10. 10.
    Vermette-Marcotte AE, Dargan PI, Archer JR, Gosselin S, Wood DM (2014) An Internet snapshot study to compare the international availability of the novel psychoactive substance methiopropamine. Clin Toxicol (Philadelphia, Pa) 52(7):678–681.  https://doi.org/10.3109/15563650.2014.933346 CrossRefGoogle Scholar
  11. 11.
    Guidance for Industry (2005) Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Pharmacology and Toxicology. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Available at https://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf%23search=%27guidekines+for+industry+sfe+starting%27. Accessed 26 July 2018
  12. 12.
    Abbate A, Scarpa S, Santini D, Palleiro J, Vasaturo F, Miller J, Morales C, Vetrovec GW, Baldi A (2006) Myocardial expression of survivin, an apoptosis inhibitor, in aging and heart failure. An experimental study in the spontaneously hypertensive rat. Int J Cardiol 111(3):371–376.  https://doi.org/10.1016/j.ijcard.2005.07.061 CrossRefGoogle Scholar
  13. 13.
    Vigolo A, Ossato A, Trapella C, Vincenzi F, Rimondo C, Seri C, Varani K, Serpelloni G, Marti M (2015) Novel halogenated derivates of JWH-018: behavioral and binding studies in mice. Neuropharmacology 95:68–82.  https://doi.org/10.1016/j.neuropharm.2015.02.008 CrossRefGoogle Scholar
  14. 14.
    Canazza I, Ossato A, Trapella C, Fantinati A, De Luca MA, Margiani G, Vincenzi F, Rimondo C, Di Rosa F, Gregori A, Varani K, Borea PA, Serpelloni G, Marti M (2016) Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies. Psychopharmacology 233(21–22):3685–3709.  https://doi.org/10.1007/s00213-016-4402-y CrossRefGoogle Scholar
  15. 15.
    Viaro R, Marti M, Morari M (2010) Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: paradoxical inhibition is relieved by D2/D3 receptor blockade. Exp Neurol 223(2):473–484.  https://doi.org/10.1016/j.expneurol.2010.01.014 CrossRefGoogle Scholar
  16. 16.
    Ossato A, Vigolo A, Trapella C, Seri C, Rimondo C, Serpelloni G, Marti M (2015) JWH-018 impairs sensorimotor functions in mice. Neuroscience 300:174–188.  https://doi.org/10.1016/j.neuroscience.2015.05.021 CrossRefGoogle Scholar
  17. 17.
    Burnside WM, Flecknell PA, Cameron AI, Thomas AA (2013) A comparison of medetomidine and its active enantiomer dexmedetomidine when administered with ketamine in mice. BMC Vet Res 9:48.  https://doi.org/10.1186/1746-6148-9-48 CrossRefGoogle Scholar
  18. 18.
    Deng J, Li J, Li L, Feng C, Xiong L, Zuo Z (2013) Glutamate transporter type 3 knockout leads to decreased heart rate possibly via parasympathetic mechanism. Transgenic Res 22(4):757–766.  https://doi.org/10.1007/s11248-012-9680-5 CrossRefGoogle Scholar
  19. 19.
    Tella SR, Schindler CW, Goldberg SR (1992) Cardiovascular effects of cocaine in conscious rats: relative significance of central sympathetic stimulation and peripheral neuronal monoamine uptake and release mechanisms. J Pharmacol Exp Ther 262(2):602–610Google Scholar
  20. 20.
    Varner KJ, Ogden BA, Delcarpio J, Meleg-Smith S (2002) Cardiovascular responses elicited by the "binge" administration of methamphetamine. J Pharmacol Exp Ther 301(1):152–159CrossRefGoogle Scholar
  21. 21.
    Baumann MH, Partilla JS, Lehner KR (2013) Psychoactive "bath salts": not so soothing. Eur J Pharmacol 698(1–3):1–5.  https://doi.org/10.1016/j.ejphar.2012.11.020 CrossRefGoogle Scholar
  22. 22.
    Schindler CW, Thorndike EB, Blough BE, Tella SR, Goldberg SR, Baumann MH (2014) Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats. Br J Pharmacol 171(1):83–91.  https://doi.org/10.1111/bph.12423 CrossRefGoogle Scholar
  23. 23.
    Schindler CW, Thorndike EB, Suzuki M, Rice KC, Baumann MH (2016) Pharmacological mechanisms underlying the cardiovascular effects of the "bath salt" constituent 3,4-methylenedioxypyrovalerone (MDPV). Br J Pharmacol 173(24):3492–3501.  https://doi.org/10.1111/bph.13640 CrossRefGoogle Scholar
  24. 24.
    Ansari A, Maron BJ, Berntson DG (2003) Drug-induced toxic myocarditis. Tex Heart Inst J 30(1):76–79Google Scholar
  25. 25.
    Phillips K, Luk A, Soor GS, Abraham JR, Leong S, Butany J (2009) Cocaine cardiotoxicity: a review of the pathophysiology, pathology, and treatment options. Am J Cardiovasc Drugs 9(3):177–196.  https://doi.org/10.2165/00129784-200909030-00005 CrossRefGoogle Scholar
  26. 26.
    Pilgrim JL, Woodford N, Drummer OH (2013) Cocaine in sudden and unexpected death: a review of 49 post-mortem cases. Forensic Sci Int 227(1–3):52–59.  https://doi.org/10.1016/j.forsciint.2012.08.037 CrossRefGoogle Scholar
  27. 27.
    Ago M, Ago K, Ogata M (2009) Determination of methamphetamine in sudden death of a traffic accident inpatient by blood and hair analyses. Legal Med (Tokyo, Japan) 11(Suppl 1):S568–S569.  https://doi.org/10.1016/j.legalmed.2009.01.086 CrossRefGoogle Scholar
  28. 28.
    Hirachan P, Agarwal R, Wagner B (2015) Cocaine: a rare cause of left-sided renal infarction. J Invest Med High Impact Case Rep 3(1):2324709615574907.  https://doi.org/10.1177/2324709615574907 Google Scholar
  29. 29.
    Fischbach P (2017) The role of illicit drug use in sudden death in the young. Cardiol Young 27(S1):S75–S79.  https://doi.org/10.1017/s1047951116002274 CrossRefGoogle Scholar
  30. 30.
    Brannan TA, Soundararajan S, Houghton BL (2004) Methamphetamine-associated shock with intestinal infarction. MedGenMed 6(4):6Google Scholar
  31. 31.
    Ekblad E, Kuhar M, Wierup N, Sundler F (2003) Cocaine- and amphetamine-regulated transcript: distribution and function in rat gastrointestinal tract. Neurogastroenterol Motil 15(5):545–557CrossRefGoogle Scholar
  32. 32.
    Tokunaga I, Kubo S, Ishigami A, Gotohda T, Kitamura O (2006) Changes in renal function and oxidative damage in methamphetamine-treated rat. Legal Med (Tokyo, Japan) 8(1):16–21.  https://doi.org/10.1016/j.legalmed.2005.07.003 CrossRefGoogle Scholar
  33. 33.
    Jaffe JA, Kimmel PL (2006) Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin J Am Soc Nephrol 1(4):655–667.  https://doi.org/10.2215/cjn.00300106 CrossRefGoogle Scholar
  34. 34.
    Leone O, Agostini V, Foa A, Cerbelli B, di Gioia CRT, Aromatario M, Ciallella C, Lucena J, d'Amati G (2017) Cardiac pathologic findings in 3 unusual cases of sudden cardiac death related to anorexiant drugs. Hum Pathol 69:101–109.  https://doi.org/10.1016/j.humpath.2017.09.014 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Federica Foti
    • 1
  • Matteo Marti
    • 2
  • Andrea Ossato
    • 1
    • 3
  • Sabrine Bilel
    • 3
  • Eugenio Sangiorgi
    • 4
  • Francesco Botrè
    • 5
    • 6
  • Bruna Cerbelli
    • 7
  • Alfonso Baldi
    • 8
  • Fabio De-Giorgio
    • 1
    Email author
  1. 1.Institute of Public Health, Section of Legal MedicineUniversità Cattolica del Sacro CuoreRomeItaly
  2. 2.Department of Morphology, Surgery and Experimental Medicine, Section of Legal MedicineUniversità di FerraraFerraraItaly
  3. 3.Department of Life Sciences and Biotechnology (SVeB)Università di FerraraFerraraItaly
  4. 4.Institute of Genomic MedicineUniversità Cattolica del Sacro CuoreRomeItaly
  5. 5.Laboratorio AntidopingFederazione Medica Sportiva ItalianaRomeItaly
  6. 6.Department of Experimental Medicine“Sapienza” UniversityRomeItaly
  7. 7.Department of Radiological, Oncological and Pathological SciencesUniversità La SapienzaRomeItaly
  8. 8.Department of Environmental, Biological and Pharmaceutical Sciences and TechnologiesUniversità della Campania L. VanvitelliCasertaItaly

Personalised recommendations